List view / Grid view


Filter the results



Cancer treatment receives EU drug designations

20 July 2016 | By Niamh Louise Marriott, Digital Content Producer

With the EU orhpan drug designations, Cell Medica can now obtain regulatory and financial incentives for developing and marketing CMD-003 as a cancer...


Ibrutinib shown to be superior to chlorambucil in trial

7 December 2015 | By Victoria White

Janssen-Cilag International NV has announced data from the Phase 3 RESONATE-2 (PCYC-1115) trial that show ibrutinib (Imbruvica) was superior to chlorambucil in all efficacy endpoints measured in patients with treatment-naïve chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) aged 65 or older.


European Commission approves additional indication for VELCADE® (bortezomib) in mantle cell lymphoma

6 February 2015 | By Janssen EMEA

Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved a variation to the terms of the marketing authorisation of VELCADE® (bortezomib) in combination with rituximab, cyclophosphamide, doxorubicin and prednisone for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for blood…